Effects of zonisamide on isolated head tremor

European Journal of Neurology

Volumn 15, Issue 11, 2008, Pages 1212-1215

  Song, I U ^a   Kim, J S ^a,c   Lee, S B ^a   Ryu, S Y ^a   An, J Y ^a   Kim, H T ^b   Kim, Y I ^a   Lee, K S ^a  

^a The Catholic University of Korea   (South Korea)

^b Hanyang University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Head tremor; Propranolol; Zonisamide

Indexed keywords

PROPRANOLOL; ZONISAMIDE;

ABDOMINAL DISCOMFORT; AGED; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL TREMOR; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD INJURY; HUMAN; MAXIMUM TOLERATED DOSE; OPTIMAL DRUG DOSE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTICONVULSANTS; CONSCIOUSNESS DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESSENTIAL TREMOR; FEMALE; HEAD MOVEMENTS; HUMANS; ISOXAZOLES; NECK MUSCLES; PATIENT COMPLIANCE; PROPRANOLOL; TREATMENT OUTCOME;

EID: 53549134431     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02296.x     Document Type: Article

References (14)

1. Louis ED, Ford B, Wendt KJ, Cameron G. Clinical characteristics of essential tremor: data from a community-based study. Movement Disorders 1998 13 : 805 808.
2. Whaley NR, Putzke JD, Baba Y, Wszolek ZK, Uitti RJ. Essential tremor: phenotypic expression in a clinical cohort. Parkinsonism & Related Disorders 2007 13 : 333 339.
3. Louis ED. Essential tremor. Lancet Neurology 2005 4 : 100 110.
4. Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Movement Disorders 2007 22 : 279 282.
5. Zesiewicz TA, Elble R, Louis ED, et al. Parctice parameter: therapies for essential tremor. Neurology 2005 64 : 2008 2020.
6. Sackellares JC, Donofrio PD, Wagner JG, Abou-Khalil B, Berent S, Aasved-Hoyt K. Pilot study of zonisamide (1,2-benzisoxazole-3- methanesulfonamide) in patients with refractory partial seizures. Epilepsia 1985 26 : 206 211.
7. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism & Related Disorders 2005 11 : 101 103.
8. Louis ED, Ford B, Bismuth B. Reliability between two observers using a protocol for diagnosing essential tremor. Movement Disorders 1998 13 : 287 293.
9. Louis ED, Ford B, Frucht S. Factors associated with increased risk or head tremor in essential tremor: a community-based study in northern Manhattan. Movement Disorders 2003 18 : 432 436.
10. Fahn SE, Tolosa E, Marin C. Clinical rating scale for tremor. In : Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders, 2nd edn. Baltimore : Williams & Wilkins, 1988 : 225 234.
11. Bermejo PE. Zonisamide in patients with essential tremor and Parkinson's disease. Movement Disorders 2007 22 : 2137 2138.
12. Ondo WG. Zonisamide for Essential Tremor. Clinical Neuropharmacology 2007 30 : 345 349.
13. Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004 13 (Suppl. 1 S5 S9.
14. Miwa H, Hama K, Kajimoto Y, Kondo T. Effects of zonisamide on experimental tremors in rats. Parkinsonism & Related Disorders 2008 14 : 33 36.